CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 3,800,000 shares, a growth of 37.7% from the April 15th total of 2,760,000 shares. Based on an average daily volume of 971,800 shares, the days-to-cover ratio is currently 3.9 days. Approximately 6.2% of the shares of the company are sold short.

Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Macquarie Group Ltd. raised its holdings in CytomX Therapeutics by 515.1% in the 3rd quarter. Macquarie Group Ltd. now owns 4,853 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 4,064 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new stake in CytomX Therapeutics in the 4th quarter valued at about $44,000. Clear Harbor Asset Management LLC purchased a new stake in CytomX Therapeutics in the 4th quarter valued at about $50,000. Metropolitan Life Insurance Co NY raised its holdings in CytomX Therapeutics by 72.2% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 11,442 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 4,796 shares during the period. Finally, BNP Paribas Arbitrage SA raised its holdings in CytomX Therapeutics by 429.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 11,619 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,426 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

A number of brokerages have recently commented on CTMX. Wedbush dropped their price objective on shares of CytomX Therapeutics from $10.00 to $6.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 10th. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. dropped their price objective on shares of CytomX Therapeutics from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. Barclays raised shares of CytomX Therapeutics from an “underweight” rating to an “overweight” rating and set a $7.00 price target on the stock in a research note on Tuesday, January 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of CytomX Therapeutics in a research note on Friday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $9.54.

Shares of CTMX opened at $1.76 on Monday. CytomX Therapeutics has a 52-week low of $1.51 and a 52-week high of $8.95. The firm’s fifty day moving average is $2.50 and its two-hundred day moving average is $4.21. The stock has a market cap of $115.10 million, a PE ratio of -1.24 and a beta of 0.76.

CytomX Therapeutics (NASDAQ:CTMXGet Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). CytomX Therapeutics had a negative return on equity of 83.08% and a negative net margin of 129.97%. During the same quarter last year, the firm posted ($0.26) EPS. On average, sell-side analysts predict that CytomX Therapeutics will post -1.44 EPS for the current year.

About CytomX Therapeutics (Get Rating)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Featured Articles

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.